Pilot Study of recurrent Ewing's Sarcoma management with Vigil/Temozolomide/Irinotecan and assessment of circulating tumor (ct) DNA.
Peter Meade AndersonMaurizio GhisoliBrian D CromptonKelly S KlegaLeonard H WexlerEmily K SlotkinLaura StanberyLuisa ManningGladice WallravenMeghan ManleyStaci HorvathErnest BognarJohn J NemunaitisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Results demonstrated safety of combination Vigil/TEM/IRI.